+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Ulcerative Colitis Market Research Report by Drug Type (Anti-TNF Biologics, Anti-inflammatory Drugs, and Calcineurin Inhibitors), Disease, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 146 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5124159
UP TO OFF until Dec 31st 2022
The United States Ulcerative Colitis Market size was estimated at USD 1,271.75 million in 2021, USD 1,459.25 million in 2022, and is projected to grow at a CAGR 11.16% to reach USD 2,399.37 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Ulcerative Colitis to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Type, the market was studied across Anti-TNF Biologics, Anti-inflammatory Drugs, Calcineurin Inhibitors, and Immunosuppressant.
  • Based on Disease, the market was studied across Fulminant Colitis, Left-sided Colitis, Pancolitis or Universal Colitis, Proctosigmoiditis, and Ulcerative Proctitis.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Ulcerative Colitis market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ulcerative Colitis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Ulcerative Colitis Market, including Abbott Laboratories, AbbVie Inc., Ajinomoto Pharmaceuticals Co., Ltd., AstraZeneca PLC, Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation, Circle33, LLC, Cosmo Pharmaceuticals NV, Eli Lilly and Company, Ferring B.V., GlaxoSmithKline PLC, InDex Pharmaceuticals Holding AB, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals Ltd, and UCB S.A..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Ulcerative Colitis Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Ulcerative Colitis Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Ulcerative Colitis Market?
4. What is the competitive strategic window for opportunities in the United States Ulcerative Colitis Market?
5. What are the technology trends and regulatory frameworks in the United States Ulcerative Colitis Market?
6. What is the market share of the leading vendors in the United States Ulcerative Colitis Market?
7. What modes and strategic moves are considered suitable for entering the United States Ulcerative Colitis Market?
Frequently Asked Questions about the U.S. Ulcerative Colitis Market

What is the estimated value of the U.S. Ulcerative Colitis Market?

The U.S. Ulcerative Colitis Market was estimated to be valued at $1271.75 Million in 2021.

What is the growth rate of the U.S. Ulcerative Colitis Market?

The growth rate of the U.S. Ulcerative Colitis Market is 11.1%, with an estimated value of $2399.37 Million by 2027.

What is the forecasted size of the U.S. Ulcerative Colitis Market?

The U.S. Ulcerative Colitis Market is estimated to be worth $2399.37 Million by 2027.

Who are the key companies in the U.S. Ulcerative Colitis Market?

Key companies in the U.S. Ulcerative Colitis Market include Abbott Laboratories, AbbVie Inc., Ajinomoto Pharmaceuticals Co., Ltd., AstraZeneca PLC, Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation and Cosmo Pharmaceuticals NV.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Ulcerative Colitis Market, by Drug Type
6.1. Introduction
6.2. Anti-TNF Biologics
6.3. Anti-inflammatory Drugs
6.4. Calcineurin Inhibitors
6.5. Immunosuppressant
7. Ulcerative Colitis Market, by Disease
7.1. Introduction
7.2. Fulminant Colitis
7.3. Left-sided Colitis
7.4. Pancolitis or Universal Colitis
7.5. Proctosigmoiditis
7.6. Ulcerative Proctitis
8. California Ulcerative Colitis Market9. Florida Ulcerative Colitis Market10. Illinois Ulcerative Colitis Market11. New York Ulcerative Colitis Market12. Ohio Ulcerative Colitis Market13. Pennsylvania Ulcerative Colitis Market14. Texas Ulcerative Colitis Market
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbott Laboratories
16.2. AbbVie Inc.
16.3. Ajinomoto Pharmaceuticals Co., Ltd.
16.4. AstraZeneca PLC
16.5. Bausch Health Companies Inc.
16.6. BioLineRx Ltd
16.7. Boehringer Ingelheim GmbH
16.8. Celgene Corporation
16.9. Circle33, LLC
16.10. Cosmo Pharmaceuticals NV
16.11. Eli Lilly and Company
16.12. Ferring B.V.
16.13. GlaxoSmithKline PLC
16.14. InDex Pharmaceuticals Holding AB
16.15. Johnson & Johnson Services, Inc.
16.16. Merck & Co., Inc.
16.17. Mitsubishi Tanabe Pharma Corporation
16.18. Novartis International AG
16.19. Pfizer Inc.
16.20. Sanofi SA
16.21. Takeda Pharmaceuticals
16.22. Teva Pharmaceuticals Ltd
16.23. UCB S.A.
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES ULCERATIVE COLITIS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES ULCERATIVE COLITIS MARKET DYNAMICS
FIGURE 8. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2027
FIGURE 11. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, 2019-2027 (USD MILLION)
FIGURE 18. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2021 VS 2027 (%)
FIGURE 20. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2021 VS 2027 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2027
FIGURE 22. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, 2019-2027 (USD MILLION)
FIGURE 23. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 24. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, 2019-2027 (USD MILLION)
FIGURE 25. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 26. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, 2019-2027 (USD MILLION)
FIGURE 27. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 28. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, 2019-2027 (USD MILLION)
FIGURE 29. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 30. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, 2019-2027 (USD MILLION)
FIGURE 31. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 32. CALIFORNIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 33. FLORIDA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 34. ILLINOIS ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. NEW YORK ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 36. OHIO ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. PENNSYLVANIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. TEXAS ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. UNITED STATES ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 40. UNITED STATES ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 41. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ULCERATIVE COLITIS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES ULCERATIVE COLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. CALIFORNIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 17. CALIFORNIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 18. CALIFORNIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 19. FLORIDA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 20. FLORIDA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 21. FLORIDA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 22. ILLINOIS ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 23. ILLINOIS ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 24. ILLINOIS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 25. NEW YORK ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 26. NEW YORK ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 27. NEW YORK ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 28. OHIO ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 29. OHIO ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 30. OHIO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 31. PENNSYLVANIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 32. PENNSYLVANIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 33. PENNSYLVANIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 34. TEXAS ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 35. TEXAS ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 36. TEXAS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 37. UNITED STATES ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 38. UNITED STATES ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 39. UNITED STATES ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 40. UNITED STATES ULCERATIVE COLITIS MARKET RANKING
TABLE 41. UNITED STATES ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 42. UNITED STATES ULCERATIVE COLITIS MARKET MERGER & ACQUISITION
TABLE 43. UNITED STATES ULCERATIVE COLITIS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 44. UNITED STATES ULCERATIVE COLITIS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 45. UNITED STATES ULCERATIVE COLITIS MARKET INVESTMENT & FUNDING
TABLE 46. UNITED STATES ULCERATIVE COLITIS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 47. UNITED STATES ULCERATIVE COLITIS MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Ajinomoto Pharmaceuticals Co., Ltd.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • BioLineRx Ltd
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Circle33, LLC
  • Cosmo Pharmaceuticals NV
  • Eli Lilly and Company
  • Ferring B.V.
  • GlaxoSmithKline PLC
  • InDex Pharmaceuticals Holding AB
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals Ltd
  • UCB S.A.

Methodology

Loading
LOADING...